Skip to main content
DeutschDE
European Commission logo print header

Immunological mechanisms of t cell activation by dendritic cells: a novel strategy for immune intervention

Ziel

The use of dendrite cells (DC) as natural adjuvant has been proposed. Aim of this project is the delivery of new therapeutic treatments of human papillomavirus (HPV) injection. The proposed strategy torn immune cell therapy is based on the use of dendrite cells (DC), which are known to be the most powerful professional antigen presenting cells of the immune system, able to prime and activate antigen-specific immune responses. The most relevant objectives are:
1) the generation of vectors for appropriable delivery of viral antigens to DC;
2) the generation of modified DC;
3) the evaluation of safety and efficacy of modified DC therapy in pre-clinical model of virally-inducedtumors;
4) Pilot clinical trial of HPV patients with antilogous DC loaded with HPV antigens. This project aims to generate a novel therapeutically strategy which requires a broad interdisciplinary approach. The proposed DC-based therapy demands the generation and validation of new therapeutic tools. One SME will contribute to the pre-clinical studies in order to be in a favourable position to exploit the results of the project.

Wissenschaftliches Gebiet

Programm/Programme

Thema/Themen

Aufforderung zur Vorschlagseinreichung

Data not available

Finanzierungsplan

CSC - Cost-sharing contracts

Koordinator

UNIVERSITÀ DEGLI STUDI DI MILANO-BICOCCA
EU-Beitrag
Keine Daten
Adresse
Piazza della Scienza 2
20126 MILANO
Italien

Auf der Karte ansehen
Gesamtkosten
Keine Daten

Beteiligte (6)

Diese Seite teilen

Herunterladen

Letzte Aktualisierung: 12 April 2005

Mein Booklet

Permalink: https://cordis.europa.eu/project/id/QLK2-CT-2000-00470/de

European Union, 2024